Women in the US and Canada with menstrually-related migraines needed to participate in an important research study
Annapolis, MD (PRWEB) May 31, 2005 -- Pharmaceutical Research Plus is seeking women with menstrually-related migraines (MRM) for participation in a clinical research study. This research study is evaluating the safety and effectiveness of an investigational oral medication in the prevention of MRM headaches.
Women in select locations throughout the United States and Canada are needed to participate in this important research study. Women interested in participating in the study should be age 15 or older, diagnosed with menstrually-related migraines, and have a documented history of MRM headaches including at least two MRM headaches in the past three months. The study is seeking women who have not received an adequate response from medications taken specifically for MRM. For more information and to determine initial eligibility, women with menstrually-related migraines are encouraged to contact Pharmaceutical Research Plus at (800) STUDY-96 (1-800-788-3996) or visit www.ClinicalTrials.com/MRM.
Participation in clinical research provides an opportunity for eligible participants to help others by contributing to medical research. New treatment options can only be made available after extensive clinical research into their effectiveness and safety.
About Menstrually-Related Migraine (MRM)
Migraine headaches affect more than 30 million people in the United States and Canada. Three times more women than men have migraines. Sixty percent of women with migraines note an increased number of headaches in association with their menstrual period. In 10% to 14% of these women, the migraines occur around the time of the period and at no other time.
Researchers believe that migraines are caused by abnormalities in genes that control the activities of cells in specific areas of the brain. Migraine symptoms include: throbbing, pulsing pain in one location of the head; sensitivity to light and sound; and nausea and/or vomiting. Some individuals experience aura prior to a migraine headache, which consists of visual disturbances such as flashing lights, zig-zag lines, or temporary vision loss.
Migraine headaches are typically brought on by triggers such as stress, lack of sleep, specific food and drink or a lack of food, or harsh environmental stimuli such as light and noise. Menstrually-related migraines are triggered by hormonal and related changes during the menstrual cycle.
Treatment
There are two approaches to treating migraines and MRM: acute treatment to relieve symptoms during a migraine headache, and preventative treatment to keep headaches from happening at all. Triptans are a family of medications developed for the acute treatment of migraines and are available as injection, nasal spray, or oral tablets. Other acute treatments include dihydroergotamine(DHE) and related chemicals, and the non-steroidal anti-inflammatory drug (NSAID) family of pain medications, including ibuprofen and naproxen.
A variety of medications are used for preventative treatment: anticonvulsants/antiepileptics, beta blockers, calcium channel blockers, antidepressants, and NSAIDs. Triptans are also being evaluated for their use in preventing headaches. Non-medical treatments used for migraines include biofeedback, relaxation therapy, acupuncture, and lifestyle changes that include avoiding migraine triggers (stress, certain foods, etc.).
Research
Not all treatments work alike in all individuals. Researchers continue to seek new treatments through clinical research studies. Clinical Research Associates® is seeking women with menstruallyrelated migraines (MRM) for participation in a nationwide clinical research study evaluating the safety and effectiveness of an investigational oral medication in the prevention of MRM headaches.
Women interested in participating in the study should be age 15 or older, diagnosed with menstrually-related migraines, and have a documented history of MRM headaches including at least two MRM headaches in the past three months. The study is seeking women who have not received an adequate response from medications taken specifically for MRM.
Participation in this research study involves six visits to a local physicians office over a period of four to six months. All qualified participants will receive study-related medical care including health assessments, lab tests, and study medication. Volunteers may then have the option to continue in the study and receive investigational medication and exams at no cost for another three months.
For more information and to determine initial eligibility, women with menstrually-related migraines are encouraged to contact Pharmaceutical Research Plus at (800) STUDY-96 (1-800-788-3996) or visit www.ClinicalTrials.com/MRM.
# # #
|
